Sapphiros invests in growth-stage diagnostic companies, focusing on technologies that prioritize innovation and patient-centric approaches.
Sapphiros has raised $30.0M in total funding. The most recent round was Series B. The last funding was announced in January 2024.
Sapphiros's investors include National Institutes of Health, Kohlberg Kravis Roberts, OraSure Technologies.
Sapphiros is headquartered in Boston, United States.
Sapphiros invests in growth-stage diagnostic companies, focusing on technologies that prioritize innovation and patient-centric approaches.
Sapphiros is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sapphiros — Funding & Investors." VCBacked, January 4, 2024, https://www.vcbacked.co/company/sapphiros. Accessed July 19, 2026.
VCBacked. (2024). Sapphiros — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/sapphiros
{{cite web |title=Sapphiros — Funding & Investors |url=https://www.vcbacked.co/company/sapphiros |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated